Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution

Brimonidine Tartrate and Timolol Maleate · BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL · Solution · Ophthalmic · Apotex Corp.

NDC 60505-0589-01 · 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 46% in a year, to $2.79 per mL — and generics that get this cheap tend to get abandoned rather than defended. 2 Class II recalls hit this product in the past year (Apotex Corp.). Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

46 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed

$85.00

Reported to Texas DSHS · 2026 annual filing · Apotex Corp

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$118,776

1,502 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

35● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

4 active manufacturers+5
Class I/II recall in past 12 months+15
price down 41% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for brimonidine tartrate and timolol maleate (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 2 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application: ANDA091442
TE code: AB
Approval date: Apr 20, 2022
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class II · OngoingMar 5, 2026
Apotex Corp. — Lack of Assurance of Sterility
Class II · OngoingSep 5, 2025
Apotex Corp. — Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Class II · OngoingMay 28, 2025
Apotex Corp. — Lack of Assurance of Sterility

Manufacturers of Brimonidine Tartrate and Timolol Maleate (Solution)

Labeler	Strength	First seen	Last seen
Caplin Steriles Limited	BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL	Jul 15, 2026	Sep 3, 2026
Apotex Corp.	BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL	Jul 15, 2026	Sep 2, 2026
Florida Pharmaceutical Products, LLC	BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL	Jul 15, 2026	Sep 2, 2026
Leading Pharma, LLC	BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution — NDC 60505-0589-01," retrieved September 3, 2026, https://drugdashboards.com/drug/60505058901.

Free to cite with attribution — see how the data is put together.